Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting
The event will feature presentations by two KOLs on the recent results from the Phase 3 program for FINTEPLA® in Dravet syndrome. Both KOLs will be available to answer questions at the conclusion of the event.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay of the presentations will be accessible here.
Forward Looking Statements
646-597-6987 | Andrew@lifesciadvisors.com
858-449-9575 | email@example.com
Source: Zogenix, Inc.